Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone781-457-9000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$113.42 million
Profitability
Miscellaneous
Employees123
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions
What is Anika Therapeutics' stock symbol?
Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
How were Anika Therapeutics' earnings last quarter?
Anika Therapeutics Inc (NASDAQ:ANIK) announced its quarterly earnings data on Thursday, February, 21st. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.22. The biotechnology company had revenue of $27 million for the quarter, compared to analysts' expectations of $26.22 million. Anika Therapeutics had a return on equity of 9.78% and a net margin of 17.66%. Anika Therapeutics's revenue was down 8.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.53 earnings per share. View Anika Therapeutics' Earnings History.
When is Anika Therapeutics' next earnings date?
What guidance has Anika Therapeutics issued on next quarter's earnings?
Anika Therapeutics updated its FY 2019 earnings guidance on Thursday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $108.722-111.888 million, compared to the consensus revenue estimate of $113.07 million.
What price target have analysts set for ANIK?
3 equities research analysts have issued twelve-month price targets for Anika Therapeutics' stock. Their predictions range from $37.00 to $48.00. On average, they expect Anika Therapeutics' share price to reach $42.50 in the next year. This suggests a possible upside of 5.0% from the stock's current price. View Analyst Price Targets for Anika Therapeutics.
What is the consensus analysts' recommendation for Anika Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Anika Therapeutics.
Has Anika Therapeutics been receiving favorable news coverage?
News stories about ANIK stock have been trending somewhat positive on Friday, InfoTrie reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Anika Therapeutics earned a news impact score of 1.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the next several days.
Who are some of Anika Therapeutics' key competitors?
Some companies that are related to Anika Therapeutics include Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), Nevro (NVRO), Tactile Systems Technology (TCMD), AtriCure (ATRC), Orthofix Medical (OFIX), Cardiovascular Systems (CSII), K2M Group (KTWO), Luminex (LMNX), Cryolife (CRY), Intersect ENT (XENT), Cerus (CERS), AngioDynamics (ANGO) and SurModics (SRDX).
What other stocks do shareholders of Anika Therapeutics own?
Who are Anika Therapeutics' key executives?
Anika Therapeutics' management team includes the folowing people:
- Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)
- Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)
- Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)
- Mr. Richard Hague, Chief Commercial Officer (Age 59)
- Mr. Alexei Goraltchouk, VP of Operations
Who are Anika Therapeutics' major shareholders?
Anika Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.87%), Kayne Anderson Rudnick Investment Management LLC (9.98%), Engaged Capital LLC (2.64%), AMI Asset Management Corp (2.27%), Bank of New York Mellon Corp (1.82%) and BTIM Corp. (1.76%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.
Which institutional investors are selling Anika Therapeutics stock?
ANIK stock was sold by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Bank of New York Mellon Corp, BlackRock Inc., Two Sigma Investments LP, Barclays PLC, Thomson Horstmann & Bryant Inc., Portolan Capital Management LLC and Engaged Capital LLC. View Insider Buying and Selling for Anika Therapeutics.
Which institutional investors are buying Anika Therapeutics stock?
ANIK stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Barrow Hanley Mewhinney & Strauss LLC, Assenagon Asset Management S.A., BTIM Corp., Ontario Teachers Pension Plan Board, Capital Management Corp VA, Squarepoint Ops LLC and Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp. View Insider Buying and Selling for Anika Therapeutics.
How do I buy shares of Anika Therapeutics?
Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Anika Therapeutics' stock price today?
One share of ANIK stock can currently be purchased for approximately $40.49.
How big of a company is Anika Therapeutics?
Anika Therapeutics has a market capitalization of $575.36 million and generates $113.42 million in revenue each year. The biotechnology company earns $31.81 million in net income (profit) each year or $1.96 on an earnings per share basis. Anika Therapeutics employs 123 workers across the globe.
What is Anika Therapeutics' official website?
How can I contact Anika Therapeutics?
Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]
MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
